Drug-protein binding kinetics in patients with type I diabetes.
Sera from 17 patients with Type I diabetes and 19 healthy volunteers have been examined to evaluate whether the kinetics of the binding of drugs to Site II of serum albumin is altered in diabetes. Stopped-flow measurements showed that the association velocity and the affinity constants of the fluorescent marker dansylsarcosine were significantly lower in diabetes (160 s-1 and 2.0 x 10(5) l.mol-1) than in non-diabetics (196 s-1 and 4.0 x 10(5) l.mol-1). The dissociation velocity was not different [20.3 s-1 vs. 19.4 s-1]. Although patients with a reduced albumin concentration were excluded the diabetics had significantly lower concentrations than the healthy volunteers. There was a significant correlation between decreased glycosylation of albumin and increased association velocity. The dissociation velocity constants were correlated with the molar concentration ratio of free fatty acids/human serum albumin. Thus, the extent of glycosylation and the amount of fatty acids bound per mole albumin can both affect the kinetics of drug binding to Site II. The lower affinity in patients with Type I diabetes is due to the increased in the glycoalbumin concentration.
Wörner
W
W
Abteilung für Klinische Pharmakologie, Johann Wolfgang Goethe-Universität, Frankfurt am Main, FRG.
Preissner
A
A
Rietbrock
N
N
D000328:Adult; D003619:Dansyl Compounds / Q000378:metabolism*; D003922:Diabetes Mellitus, Type 1 / Q000378:metabolism*; D006801:Humans; D008875:Middle Aged; D011485:Protein Binding; D012521:Sarcosine / Q000031:analogs & derivatives* / Q000378:metabolism; D012709:Serum Albumin / Q000378:metabolism*
D003619:Dansyl Compounds; D012709:Serum Albumin; C037087:dansylsarcosine; D012521:Sarcosine